A5078389632- Lung Cancer Treatments and Mutations
- Lung Cancer Research Studies
- Cancer Immunotherapy and Biomarkers
- Colorectal Cancer Treatments and Studies
- Lung Cancer Diagnosis and Treatment
- Cancer therapeutics and mechanisms
- Cancer Treatment and Pharmacology
- Neuroendocrine Tumor Research Advances
- Cancer Genomics and Diagnostics
- Hepatocellular Carcinoma Treatment and Prognosis
- Immunotherapy and Immune Responses
- HER2/EGFR in Cancer Research
- Peptidase Inhibition and Analysis
- Angiogenesis and VEGF in Cancer
- Inflammatory mediators and NSAID effects
- Lymphoma Diagnosis and Treatment
- Gastric Cancer Management and Outcomes
- Cancer, Hypoxia, and Metabolism
- CAR-T cell therapy research
- Estrogen and related hormone effects
- Global Cancer Incidence and Screening
- Ethics in Clinical Research
- Radiomics and Machine Learning in Medical Imaging
- Sarcoma Diagnosis and Treatment
- Head and Neck Cancer Studies
S. M. Kirov Military Medical Academy
2024
Roche (United States)
2018
The Maria Sklodowska-Curie National Research Institute of Oncology
2018
Chinese University of Hong Kong
2018
Georgetown University
2018
LungenClinic Grosshansdorf
2018
Tennessee Oncology
2018
German Center for Lung Research
2018
Dana-Farber Cancer Institute
2005-2017
La Roche College
2017
Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, has been shown to benefit patients with variety of cancers.Between July 2001 and April 2004, the Eastern Cooperative Oncology Group (ECOG) conducted randomized study in which 878 recurrent or advanced non-small-cell lung cancer (stage IIIB IV) were assigned chemotherapy paclitaxel carboplatin alone (444) plus bevacizumab (434). Chemotherapy was administered every 3 weeks for six cycles, until disease progression...
We conducted a randomized study to determine whether any of three chemotherapy regimens was superior cisplatin and paclitaxel in patients with advanced non–small-cell lung cancer.
The cancer-cell-killing property of atezolizumab may be enhanced by the blockade vascular endothelial growth factor-mediated immunosuppression with bevacizumab. This open-label, phase 3 study evaluated plus bevacizumab chemotherapy in patients metastatic nonsquamous non-small-cell lung cancer (NSCLC) who had not previously received chemotherapy.We randomly assigned to receive carboplatin paclitaxel (ACP), (BCP), or BCP (ABCP) every weeks for four six cycles, followed maintenance therapy...
Enhancing tumor-specific T-cell immunity by inhibiting programmed death ligand 1 (PD-L1)–programmed (PD-1) signaling has shown promise in the treatment of extensive-stage small-cell lung cancer. Combining checkpoint inhibition with cytotoxic chemotherapy may have a synergistic effect and improve efficacy.
More persons in the United States die from non-small cell lung cancer (NSCLC) than breast, colorectal, and prostate combined. In preclinical testing, oral gefitinib inhibited growth of NSCLC tumors that express epidermal factor receptor (EGFR), a mediator signaling, phase 1 trials have demonstrated fraction patients with progressing after chemotherapy experience both decrease symptoms radiographic tumor shrinkages gefitinib.To assess differences symptomatic response among receiving 250-mg...
Erlotinib is a potent reversible HER1/epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor with single-agent activity in patients non-small-cell lung cancer (NSCLC). was combined chemotherapy to determine if it could improve the outcome of NSCLC.TRIBUTE randomly assigned good performance status and previously untreated advanced (stage IIIB/IV) NSCLC erlotinib 150 mg/d or placebo up six cycles carboplatin paclitaxel, followed by maintenance monotherapy erlotinib. Random...
The efficacy and safety of the anti-programmed death ligand 1 (PD-L1) monoclonal antibody atezolizumab, as compared with those platinum-based chemotherapy, first-line treatment for patients metastatic non-small-cell lung cancer (NSCLC) PD-L1 expression are not known.We conducted a randomized, open-label, phase 3 trial involving nonsquamous or squamous NSCLC who had previously received chemotherapy on at least 1% tumor cells tumor-infiltrating immune assessed by SP142 immunohistochemical...
Purpose Etoposide and cisplatin (EP) has been a standard treatment for extensive-disease small-cell lung cancer (SCLC). An earlier phase III trial reported improved survival patients receiving irinotecan plus (IP) versus EP. Our was designed to determine if modified weekly regimen of IP would provide superior with less toxicity than Patients Methods The primary objective compare overall in SCLC randomly assigned receive (n = 221) or EP 110). were 2:1 ratio 30 mg/m 2 intravenously (IV) + 65...
Bevacizumab (Avastin; Genentech, South San Francisco, CA) is a recombinant, humanized anti-vascular endothelial growth factor monoclonal antibody. Erlotinib HCl (Tarceva, OSI-774; OSI Pharmaceuticals, New York, NY) potent, reversible, highly selective and orally available HER-1/epidermal receptor tyrosine kinase inhibitor. Preclinical data in various xenograft models produced greater inhibition than with either agent alone. Additionally, both agents have demonstrated benefit patients...
Cytotoxic agents have immunomodulatory effects, providing a rationale for combining atezolizumab (anti-programmed death-ligand 1 [anti-PD-L1]) with chemotherapy. The randomized phase III IMpower131 study (NCT02367794) evaluated platinum-based chemotherapy in stage IV squamous NSCLC.A total of 1021 patients were 1:1:1 to receive atezolizumab+carboplatin+paclitaxel (A+CP) (n = 338), atezolizumab+carboplatin+nab-paclitaxel (A+CnP) 343), or carboplatin+nab-paclitaxel (CnP) 340) four six 21-day...
Bevacizumab, a humanized anti-vascular endothelial growth factor monoclonal antibody, and erlotinib, reversible, orally available epidermal receptor tyrosine kinase inhibitor, have demonstrated evidence of survival benefit in the treatment non-small-cell lung cancer (NSCLC). A single-arm phase I II study bevacizumab plus erlotinib encouraging efficacy, with favorable safety profile.A multicenter, randomized trial evaluated combining either chemotherapy (docetaxel or pemetrexed) preliminarily...
Purpose BIRCH was designed to examine the efficacy of atezolizumab, a humanized anti–programmed death-ligand 1 (PD-L1) monoclonal antibody, in advanced non–small-cell lung cancer (NSCLC) across lines therapy. Patients were selected on basis PD-L1 expression tumor cells (TC) or tumor-infiltrating immune (IC). and Methods Eligible patients had advanced-stage NSCLC, no CNS metastases, zero two more prior chemotherapy. whose tumors expressed using SP142 immunohistochemistry assay ≥ 5% TC IC...
We conducted a basket clinical trial to assess the feasibility of such design strategy and independently evaluate effects multiple targeted agents against specific molecular aberrations in histologic subtypes concurrently.We enrolled patients with advanced non-small-cell lung cancer (NSCLC), small-cell cancer, thymic malignancies who underwent genomic characterization oncogenic drivers. Patients were onto not-otherwise-specified arm treated standard-of-care therapies or one following five...
Abstract Purpose: Ganetespib is a novel inhibitor of the heat shock protein 90 (Hsp90), chaperone critical to tumor growth and proliferation. In this phase II study, we evaluated activity tolerability ganetespib in previously treated patients with non–small cell lung cancer (NSCLC). Experimental Design: Patients were enrolled into cohort A (mutant EGFR), B KRAS), or C (no EGFR KRAS mutations). 200 mg/m2 by intravenous infusion once weekly for 3 weeks followed 1 week rest, until disease...
Significance Programmed death-ligand 1 (PD-L1) expression on tumor cells and tumor-infiltrating immune is regulated by distinct mechanisms has nonredundant roles in regulating anticancer immunity, PD-L1 both cell types important for predicting best response to atezolizumab non-small lung cancer.
Abstract Purpose: Poly(ADP-ribose) polymerase-1 (PARP-1) is the founding member of a family enzymes that catalyze addition ADP-ribose units to proteins mediate DNA repair pathways. Ionizing radiation induces strand breaks, suggesting PARP-1 inhibition may sensitize tumor cells radiation. Experimental Design: We investigated combination with in lung cancer models. ABT-888, novel potent inhibitor, was used explore effects on irradiated tumors and vasculature. Results: ABT-888 reduced...
This phase II study evaluated efficacy and safety of single-agent axitinib, an oral, potent, selective inhibitor vascular endothelial growth factor receptors (VEGFR) -1, -2, -3, in patients with advanced non-small-cell lung cancer (NSCLC).This was open-label, single-arm, multicenter, a Simon two-stage minimax design. Patients received starting dose axitinib 5 mg orally BID. The primary end point Response Evaluation Criteria Solid Tumors (RECIST) -defined objective response rate. Secondary...